iCoreConnect Provides Update on Post Business Combination Share Exchange
OCOEE, FL, Aug. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – iCoreConnect, Inc. (NASDAQ:ICCT) ("iCore" or the "Company"), a cloud-based software and technology company focused on increasing workflow productivity and customer profitability through its enterprise and healthcare workflow platform, today provided an update on recent trading activity following the close of its business combination with FG Merger Corp. ("FGMC" (Nasdaq: FGMC), a special purpose acquisition corporation. Today, trading of ICCT's securities was halted on Nasdaq when it was identified that certain shares did not convert using the post-business combination exchange ratio. The situation has been corrected and the Company will resume trading at market open on Wednesday, August 30, 2023.
Shareholders seeking additional information on how this may impact their individual positions should contact their respective brokerage firms.
About iCoreConnect, Inc.
iCoreConnect, Inc. is a cloud-based software and technology company focused on increasing workflow productivity and practice profitability through its enterprise and healthcare workflow platform of applications and services. iCoreConnect is most notably known for its innovation in solving healthcare business problems. iCoreConnect's philosophy places a high value on customer feedback, allowing iCoreConnect to respond to the market's needs. iCoreConnect touts a platform of 16 SaaS enterprise solutions and more than 100 product endorsements with state or regional healthcare associations across the United States.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the Company's revenue and annualized recurring revenue estimates for 2023, the Company's ability to grow opportunities within ePrescription and insurance verification, and the Company's ability to continue to expand its reach into medical customers. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ‘believes,' ‘estimates,' ‘anticipates,' ‘expects,' ‘plans,' ‘projects,' ‘intends,' ‘potential,' ‘may,' ‘could,' ‘might,' ‘will,' ‘should,' ‘approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in the Company's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contacts:
Davis Snyder or Nick Nelson
312-445-2870
[email protected]
